Oxaliplatin-based chemotherapy in patients with advanced neuroendocrine carcinoma: an Italian retrospective multicenter analysis


Introduction: Conventional chemotherapy does not have a well-defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs). Various regimens were evaluated. Cisplatin or carboplatin combined with etoposide are usually indicated in poorly differentiated (PD) NECs. Some evidence exists for oxaliplatin activity in WD and PD NECs, combined with capecitabine or gemcitabine.

Aim(s): To evaluate the activity and toxicity of oxaliplatin-based chemotherapy in patients with advanced NECs.

Materials and methods: We reviewed the clinical records of patients with a histological diagnosis of NECs, progressive advanced unresectable disease, treated with an oxaliplatin-based regimen. The tumors were defined according to WHO 2000 and TNM 2006 classifications. Response rate (RR), time to progression (TTP), toxicity, and survival were calculated. The tissue tumor samples were centrally (IEO) analysed to detect Ki-67, and excision repair cross-complementing group-1 (ERCC-1).

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Spada F

Authors: Spada F, Nobili E, Ricasoli M, Scarabelli L, Pelosi G,

Keywords: neuroendocrine tumors, oxaliplatin, ERCC1, Ki 67 ,

To read the full abstract, please log into your ENETS Member account.